{
    "nctId": "NCT01606748",
    "briefTitle": "A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin",
    "officialTitle": "An Open-Label, Non-controlled, Non-randomized Sequential Design, Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin in Patients With Advanced Solid Cancers",
    "overallStatus": "COMPLETED",
    "conditions": "Malignant Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have documented advanced or metastatic malignant solid tumors (except for colorectal tumors with KRAS mutation) that are resistant to standard therapy or for which no standard therapy is available\n* May have measurable or non-measurable disease\n* Have resolution to Grade 0 or 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE 4.0) of all clinically significant toxic effects (other than alopecia) of prior chemotherapy, surgery, radiotherapy, or hormonal therapy\n* Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1\n* Have adequate hepatic, hematologic and renal function\n* If female, are surgically sterile, postmenopausal, or agree to be compliant with a highly effective contraceptive method during and for 6 months after the treatment period. If male, are surgically sterile or agree to be compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period\n* Female participants of childbearing potential have a negative serum pregnancy test within 7 days prior to the first dose of study therapy\n\nExclusion Criteria:\n\n* Have received a systemic anticancer agent (including EGFR tyrosine kinase inhibitors) or device within 28 days prior to first dose of study therapy\n* The most recent anticancer therapy received by the participant included either gemcitabine or cisplatin (or both)\n* Have received radiotherapy within 14 days prior to first dose of study therapy\n* Have received cytotoxic chemotherapy within 21 days prior to first dose of study therapy\n* Are receiving concurrent treatment with another anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy, chemoembolization, or targeted therapy\n* Are considered surgical candidates (with resectable disease)\n* Have brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants\n* Have narrowing of or blockage in large veins\n* Have coronary artery disease or uncontrolled congestive heart failure\n* Have uncontrolled angina pectoris, or experienced myocardial infarction within 6 months prior to first dose of study therapy\n* Have an ongoing or active infection (requiring treatment), including active tuberculosis or known infection with the human immunodeficiency virus\n* Have a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder\n* Have known drug or alcohol abuse\n* If female, are pregnant or breastfeeding\n* Have had major surgery within 28 days prior to first dose of study medication or subcutaneous venous access device implantation within 7 days prior to first dose of study therapy\n* Are currently enrolled in, or discontinued within the 30 days prior to first dose of study therapy from a clinical trial involving an investigational product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}